PalellaFJJr, DelaneyKM, MoormanAC, Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med1998;338:853–60
2.
da SilvaEF, BárbaroG. New options in the treatment of lipid disorders in HIV-infected patients. Open AIDS J2009;3:31–7
3.
PowerR, TateHL, McGillSM, TaylorC. A qualitative study of the psychosocial implications of lipodystrophy syndrome on HIV positive individuals. Sex Transm Infect2003;79:137–41
4.
MallonPW, MillerJ, KovacicJC, Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men – a randomized, placebo-controlled study. AIDS2006;20:1003–10
5.
DubéMP, SteinJH, AbergJA, Adult AIDS Clinical Trials Group Cardiovascular Subcommittee; HIV Medical Association of the Infectious Disease Society of America. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis2003;37:613–27
6.
FichtenbaumCJ, GerberJG, RosenkranzSL, NIAID AIDS Clinical Trials Group. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS2002;16:569–77
